Form 8-K - Current report:
SEC Accession No. 0001437749-20-024647
Filing Date
2020-12-01
Accepted
2020-12-01 16:15:33
Documents
16
Period of Report
2020-12-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20201201_8k.htm   iXBRL 8-K 24232
2 EXHIBIT 99.1 ex_216003.htm EX-99.1 9575
7 logo.jpg GRAPHIC 5278
8 logolg.jpg GRAPHIC 6757
  Complete submission text file 0001437749-20-024647.txt   198031

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20201201.xsd EX-101.SCH 3700
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20201201_def.xml EX-101.DEF 11972
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20201201_lab.xml EX-101.LAB 16010
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20201201_pre.xml EX-101.PRE 12181
9 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20201201_8k_htm.xml XML 2656
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 201361032
SIC: 2834 Pharmaceutical Preparations